FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236099859> ?p ?o ?g. }

• W4236099859 endingPage "967" @default.
• W4236099859 startingPage "967" @default.
• W4236099859 abstract "Abstract Abstract 967 A PROGNOSTIC MODEL OF THERAPY-RELATED MYELODYSPLASTIC SYNDROME FOR PREDICTING SURVIVAL AND TRANSFORMATION TO ACUTE MYELOID LEUKEMIA Alfonso Quintás-Cardama, Hawk Kim, Elias Jabbour, Stefan Faderl, William Wierda, Farhad Ravandi, Tapan Kadia, Sa Wang, Sherry Pierce, Jianqin Shan, Hagop Kantarjian, Guillermo Garcia-Manero Background: A significant fraction of patients with MDS have a prior history of an antecedent malignancy treated with chemotherapy and/or radiotherapy. Therapy related MDS (t-MDS) differs from de novo MDS in its high frequency of chromosomal abnormalities (typically in the context of complex karyotypes), high rate of transformation to acute myeloid leukemia (AML), and high resistance to standard MDS therapy. MDS prognostic models (e.g., IPSS, WPSS) have been developed based primarily on cohorts of patients with de novo MDS. We evaluated the characteristics of a large cohort of patients with t-MDS and created a specific t-MDS prognostic model. Patients and methods: From 1998 to 2007, we identified 1950 patients with MDS of which 438 (22%) (RAEB-T by FAB were excluded) had a history of one or more prior malignancies and treatment for their malignancies prior to a diagnosis of MDS. Of those, 279 (64%) had received prior chemotherapy and/or radiotherapy, and therefore were categorized as t-MDS. Potential prognostic factors were determined by univariate analyses and validated by multivariate analysis. The final prognostic factors were incorporated into a novel prognostic model. Results: Univariate analysis identified significant factors in association with overall survival. They included hepatomegaly (no vs. yes; p=0.02), hemoglobin (<9.9 vs. 10.0–11.9 vs. ≥ 12.0; p<0.001), platelet (<30 vs. 30–49 vs. 50–199 vs. ≥ 200; p<0.001), marrow blast% (<5, 5–10 and 11–19; p <0.001), cytogenetics (5q-, 20q-, Y-, normal vs. others vs. 7- and/or complex; p<0.001), types of MDS by WHO classification (RA, RCMD, MDSu vs. others; p<0.001), time from treatment to MDS (≤5 vs. >5 years; p=0.06), number of lines of therapy (1 vs. ≥2; p=0.06), serum albumin (≥4 vs. <4g/dL; p=0.01), serum β-2 microglobulin (≤3 vs. >3mg/L; p=0.05), ECOG performance status (0–1 vs. ≥2; p<0.001), and prior transfusion (p<0.001). When incorporated into the multivariate model, we identified 7 factors that independently predicted survival: age (≥65yrs vs <65yrs; HR=1.63), ECOG performance status (2–4 vs. 0–1; HR=1.86), cytogenetics (−7 and/or complex vs others; HR=2.47), WHO MDS subtype (RARs, RAEB-1/2 vs others; HR=1.92), hemoglobin (<11g/dL vs ≥11.0 g/dL; HR=2.24), platelets (<50 vs ≥50; HR=2.01), and transfusion dependency (yes vs no; HR=1.59). These factors were then used to create a prognostic model that segregates patients into 3 discreet prognostic groups: good (n=57, 21%; 0–2 risk factors; median survival 34 months), intermediate (n=154, 57%; 3–4 risk factors; median survival 12 months) and poor (n=61, 22%; 5–7 risk factors; median survival 5 months) (Figure 1A). This model also predicted 1-year leukemia free survival (good: 96%, intermediate: 84%, and poor: 72%; p=0.001). This model was subsequently validated in a test group of 189 patients with t-MDS diagnosed between 2008 and 2010. The median survival rates for low, intermediate, and poor risk patients in this group were: 26, 13, and 7 months (p<0.001) (Figure 1B). Conclusion: We propose a prognostic model specific for patients with t-MDS that predicts overall and leukemia-free survivals. This model may facilitate the development of risk-adapted therapeutic strategies. Disclosures: No relevant conflicts of interest to declare." @default.
• W4236099859 created "2022-05-12" @default.
• W4236099859 creator A5000750846 @default.
• W4236099859 creator A5020340537 @default.
• W4236099859 creator A5026159318 @default.
• W4236099859 creator A5026347795 @default.
• W4236099859 creator A5038107984 @default.
• W4236099859 creator A5049385583 @default.
• W4236099859 creator A5049891346 @default.
• W4236099859 creator A5059555096 @default.
• W4236099859 creator A5061026876 @default.
• W4236099859 creator A5084379902 @default.
• W4236099859 creator A5089295627 @default.
• W4236099859 creator A5089428686 @default.
• W4236099859 date "2011-11-18" @default.
• W4236099859 modified "2023-10-15" @default.
• W4236099859 title "A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia" @default.
• W4236099859 doi "https://doi.org/10.1182/blood.v118.21.967.967" @default.
• W4236099859 hasPublicationYear "2011" @default.
• W4236099859 type Work @default.
• W4236099859 citedByCount "0" @default.
• W4236099859 crossrefType "journal-article" @default.
• W4236099859 hasAuthorship W4236099859A5000750846 @default.
• W4236099859 hasAuthorship W4236099859A5020340537 @default.
• W4236099859 hasAuthorship W4236099859A5026159318 @default.
• W4236099859 hasAuthorship W4236099859A5026347795 @default.
• W4236099859 hasAuthorship W4236099859A5038107984 @default.
• W4236099859 hasAuthorship W4236099859A5049385583 @default.
• W4236099859 hasAuthorship W4236099859A5049891346 @default.
• W4236099859 hasAuthorship W4236099859A5059555096 @default.
• W4236099859 hasAuthorship W4236099859A5061026876 @default.
• W4236099859 hasAuthorship W4236099859A5084379902 @default.
• W4236099859 hasAuthorship W4236099859A5089295627 @default.
• W4236099859 hasAuthorship W4236099859A5089428686 @default.
• W4236099859 hasConcept C126322002 @default.
• W4236099859 hasConcept C143998085 @default.
• W4236099859 hasConcept C144301174 @default.
• W4236099859 hasConcept C151730666 @default.
• W4236099859 hasConcept C2778729363 @default.
• W4236099859 hasConcept C2779343474 @default.
• W4236099859 hasConcept C2780007613 @default.
• W4236099859 hasConcept C2780240888 @default.
• W4236099859 hasConcept C2780817109 @default.
• W4236099859 hasConcept C38180746 @default.
• W4236099859 hasConcept C509974204 @default.
• W4236099859 hasConcept C71924100 @default.
• W4236099859 hasConcept C86803240 @default.
• W4236099859 hasConceptScore W4236099859C126322002 @default.
• W4236099859 hasConceptScore W4236099859C143998085 @default.
• W4236099859 hasConceptScore W4236099859C144301174 @default.
• W4236099859 hasConceptScore W4236099859C151730666 @default.
• W4236099859 hasConceptScore W4236099859C2778729363 @default.
• W4236099859 hasConceptScore W4236099859C2779343474 @default.
• W4236099859 hasConceptScore W4236099859C2780007613 @default.
• W4236099859 hasConceptScore W4236099859C2780240888 @default.
• W4236099859 hasConceptScore W4236099859C2780817109 @default.
• W4236099859 hasConceptScore W4236099859C38180746 @default.
• W4236099859 hasConceptScore W4236099859C509974204 @default.
• W4236099859 hasConceptScore W4236099859C71924100 @default.
• W4236099859 hasConceptScore W4236099859C86803240 @default.
• W4236099859 hasIssue "21" @default.
• W4236099859 hasLocation W42360998591 @default.
• W4236099859 hasOpenAccess W4236099859 @default.
• W4236099859 hasPrimaryLocation W42360998591 @default.
• W4236099859 hasRelatedWork W1093006 @default.
• W4236099859 hasRelatedWork W1605945 @default.
• W4236099859 hasRelatedWork W24205292 @default.
• W4236099859 hasRelatedWork W24410202 @default.
• W4236099859 hasRelatedWork W24808951 @default.
• W4236099859 hasRelatedWork W4527439 @default.
• W4236099859 hasRelatedWork W4563157 @default.
• W4236099859 hasRelatedWork W5342291 @default.
• W4236099859 hasRelatedWork W806154 @default.
• W4236099859 hasRelatedWork W893036 @default.
• W4236099859 hasVolume "118" @default.
• W4236099859 isParatext "false" @default.
• W4236099859 isRetracted "false" @default.
• W4236099859 workType "article" @default.